EGFR signaling patterns are regulated by its different ligands

Growth Factors

Volumn 32, Issue 5, 2014, Pages 155-163

  Knudsen, Stine Louise Jeppe ^a,b   Wai Mac, Anni Sieu ^a   Henriksen, Lasse ^a,c   Van Deurs, Bo ^a   Grøvdal, Lene Melsæther ^a,d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c H LUNDBECK A S   (Denmark)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

BTC; EGF; EGF receptor; HB EGF; signaling; TGF

Indexed keywords

BETACELLULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOLIPASE C GAMMA; PROTEIN KINASE B; STAT PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERBB4 PROTEIN, HUMAN; MAPK1 PROTEIN, HUMAN; PROTEIN BINDING; PROTEOHEPARAN SULFATE; STAT3 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BINDING AFFINITY; CELL FUNCTION; CELL STIMULATION; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIMERIZATION; DOWNSTREAM PROCESSING; ENDOCYTOSIS; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FEMALE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; INTERNALIZATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; BINDING COMPETITION; HELA CELL LINE; METABOLISM; PHOSPHORYLATION;

BINDING, COMPETITIVE; EPIDERMAL GROWTH FACTOR; HELA CELLS; HEPARAN SULFATE PROTEOGLYCANS; HEPARIN-BINDING EGF-LIKE GROWTH FACTOR; HUMANS; INHIBITORY CONCENTRATION 50; LIGANDS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHOLIPASE C GAMMA; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-4; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84925241154     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2014.952410     Document Type: Article

References (70)

1. Aviezer D, Yayon A. 1994. Heparin-dependent binding and autophosphorylation of epidermal growth factor (EGF) receptor by heparin-binding EGF-like growth factor but not by EGF. Proc Natl Acad Sci USA 91:12173-12177.
2. Benelli R, Vene R, Minghelli S, Carlone S, Gatteschi B, Ferrari N. 2013. Celecoxib induces proliferation and Amphiregulin production in colon subepithelial myofibroblasts, activating erk1-2 signaling in synergy with EGFR. Cancer Lett 328:73-82.
3. Bjorkelund H, Gedda L, Andersson K. 2011. Comparing the epidermal growth factor interaction with four different cell lines: Intriguing effects imply strong dependency of cellular context. PLoS One 6: e16536.
4. Burke P, Schooler K, Wiley HS. 2001. Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell 12:1897-1910.
5. Cohen S, Carpenter G. 1975. Human epidermal growth factor: Isolation and chemical and biological properties. Proc Natl Acad Sci USA 72: 1317-1321.
6. De Larco JE, Todaro GJ. 1978. Growth factors from murine sarcoma virus-transformed cells. Proc Natl Acad Sci USA 75:4001-4005.
7. Ebner R, Derynck R. 1991. Epidermal growth factor and transforming growth factor-alpha: Differential intracellular routing and processing of ligand-receptor complexes. Cell Regul 2:599-612.
8. Elenius K, Paul S, Allison G, Sun J, Klagsbrun M. 1997. Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J 16:1268-1278.
9. Ferrer-Soler L, Vazquez-Martin A, Brunet J, De Menendez JA, Llorens R, Colomer R. 2007. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). Int J Mol Med 20:3-10.
10. Harris RC, Chung E, Coffey RJ. 2003. EGF receptor ligands. Exp Cell Res 284:2-13.
11. Haugh JM. 2002. Localization of receptor-mediated signal transduction pathways: The inside story. Mol Interv 2:292-307.
12. Hayashi T, Sakamoto S. 1988. Radioimmunoassay of human epidermal growth factor hEGF levels in human body fluids. J Pharmacobiodyn 11:146-151.
13. Henriksen L, Grandal MV, Knudsen SL, van Deurs B, Grovdal LM. 2013. Internalization mechanisms of the epidermal growth factor receptor after activation with different ligands. PLoS One 8:e58148.
14. Higashiyama S, Abraham JA, Klagsbrun, M. 1993. Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: Dependence on interactions with cell surface heparan sulfate. J Cell Biol 122:933-940.
15. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M. 1991. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 251:936-939.
16. Hikita S, Yotsumoto F, Fukami T, Horiuchi S, Sanui A, Miyata K, Nam SO, et al. 2011. Assessment of HB-EGF levels in peritoneal fluid and serum of ovarian cancer patients using ELISA. Anticancer Res 31: 2553-2559.
17. Iwamoto R, Mekada E. 2000. Heparin-binding EGF-like growth factor: A juxtacrine growth factor. Cytokine Growth Factor Rev 11:335-344.
18. Jiang X, Huang F, Marusyk A, Sorkin A. 2003. Grb2 regulates internalization of EGF receptors through clathrin-coated pits. Mol Biol Cell 14:858-870.
19. Jin K, Mao XO, Del Rio, Guerra G, Jin L, Greenberg DA. 2005. Heparin-binding epidermal growth factor-like growth factor stimulates cell proliferation in cerebral cortical cultures through phosphatidylinositol 3′-kinase and mitogen-activated protein kinase. J Neurosci Res 81:497-505.
20. Joh T, Itoh M, Katsumi K, Yokoyama Y, Takeuchi T, Kato T, Wada Y, Tanaka R. 1986. Physiological concentrations of human epidermal growth factor in biological fluids: Use of a sensitive enzyme immunoassay. Clin Chim Acta 158:81-90.
21. Jones JT, Akita RW, Sliwkowski MX. 1999. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 447:227-231.
22. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. 2003. Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp Cell Res 284:31-53.
23. Klein P, Mattoon D, Lemmon MA, Schlessinger J. 2004. A structure-based model for ligand binding and dimerization of EGF receptors. Proc Natl Acad Sci USA 101:929-934.
24. Kochupurakkal BS, Harari D, Di-Segni A, Maik-Rachline G, Lyass L, Gur G, Kerber G, et al. 2005. Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. J Biol Chem 280:8503-8512.
25. Krall JA, Beyer EM, MacBeath G. 2011. High- and low-affinity epidermal growth factor receptor-ligand interactions activate distinct signaling pathways. PLoS One 6:e15945.
26. Lemmon MA. 2009. Ligand-induced ErbB receptor dimerization. Exp Cell Res 315:638-648.
27. Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, Schirripa M, et al. 2013. EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Target Oncol [Epub ahead of print]. doi:10.1007/s11523-013-0284-7.
28. Lund KA, Lazar CS, Chen WS, Walsh BJ, Welsh JB, Herbst JJ, Walton GM, et al. 1990. Phosphorylation of the epidermal growth factor receptor at threonine 654 inhibits ligand-induced internalization and down-regulation. J Biol Chem 265:20517-20523.
29. Luwor RB, Chin X, McGeachie AB, Robinson PJ, Zhu HJ. 2012. Dynamin II function is required for EGF-mediated Stat3 activation but not Erk1/2 phosphorylation. Growth Factors 30:220-229.
30. Moskal TL, Huang S, Ellis LM, Fritsche Jr HA, Chakrabarty S. 1995. Serum levels of transforming growth factor alpha in gastrointestinal cancer patients. Cancer Epidemiol Biomarkers Prev 4:127-131.
31. Mummery RS, Mulloy B, Rider CC. 2007. The binding of human betacellulin to heparin, heparan sulfate and related polysaccharides. Glycobiology 17:1094-1103.
32. Nedergaard MK, Hedegaard CJ, Poulsen HS. 2012. Targeting the epidermal growth factor receptor in solid tumor malignancies. BioDrugs 26:83-99.
33. Normanno N, Ciardiello F, Brandt R, Salomon DS. 1994. Epidermal growth factor-related peptides in the pathogenesis of human breast cancer. Breast Cancer Res Treat 29:11-27.
34. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, De Carotenuto A, et al. 2006. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:2-16.
35. Oliver BL, Sha'afi RI, Hajjar JJ. 1995. Transforming growth factor-alpha and epidermal growth factor activate mitogen-activated protein kinase and its substrates in intestinal epithelial cells. Proc Soc Exp Biol Med 210:162-170.
36. Quesnelle KM, Boehm AL, Grandis JR. 2007. STAT-mediated EGFR signaling in cancer. J Cell Biochem 102:311-319.
37. Rayego-Mateos S, Rodrigues-Diez R, Morgado-Pascual JL, Rodrigues Diez RR, Mas S, Lavoz C, Alique M, et al. 2013. Connective tissue growth factor is a new ligand of epidermal growth factor receptor. J Mol Cell Biol 5:323-335.
38. Revillion F, Lhotellier V, Hornez L, Bonneterre J, Peyrat JP. 2008. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol 19: 73-80.
39. Riese DJ, Bermingham Y, van Raaij TM, Buckley S, Plowman GD, Stern DF. 1996. Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta. Oncogene 12:345-353.
40. Riese DJ, Komurasaki T, Plowman GD, Stern DF. 1998. Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2. J Biol Chem 273: 11288-11294.
41. Rizzolio S, Rabinowicz N, Rainero E, Lanzetti L, Serini G, Norman J, Neufeld G, Tamagnone L. 2012. Neuropilin-1-dependent regulation of EGF-receptor signaling. Cancer Res 72:5801-5811.
42. Roberts PJ, Der CJ. 2007. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291-3310.
43. Roepstorff K, Grandal MV, Henriksen L, Knudsen SL, Lerdrup M, Grovdal L, Willumsen BM, van Deurs B. 2009. Differential effects of EGFR ligands on endocytic sorting of the receptor. Traffic 10:1115-1127.
44. Roepstorff K, Grovdal L, Grandal M, Lerdrup M, van Deurs B. 2008. Endocytic downregulation of ErbB receptors: Mechanisms and relevance in cancer. Histochem Cell Biol 129:563-578.
45. Rutten MJ, Dempsey PJ, Solomon TE, Coffey Jr RJ. 1993. TGF-alpha is a potent mitogen for primary cultures of guinea pig gastric mucous epithelial cells. Am J Physiol 265:G361-G369.
46. Sadowski L, Pilecka I, Miaczynska M. 2009. Signaling from endosomes: Location makes a difference. Exp Cell Res 315:1601-1609.
47. Sanchez-Vizcaino E, Vehi C, Camprecios G, Morcillo C, Soley M, Ramirez I. 2010. Heparin-binding EGF-like growth factor in human serum. Association with high blood cholesterol and heart hypertrophy. Growth Factors 28:98-103.
48. Sanders JM, Wampole ME, Thakur ML, Wickstrom E. 2013. Molecular determinants of epidermal growth factor binding: A molecular dynamics study. PLoS One 8:e54136.
49. Sasada R, Ono Y, Taniyama Y, Shing Y, Folkman J, Igarashi K. 1993. Cloning and expression of cDNA encoding human betacellulin, a new member of the EGF family. Biochem Biophys Res Commun 190:1173-1179.
50. Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U. 2002. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2:521-528.
51. Schneider MR, Wolf E. 2009. The epidermal growth factor receptor ligands at a glance. J Cell Physiol 218:460-466.
52. Shing Y, Christofori G, Hanahan D, Ono Y, Sasada R, Igarashi K, Folkman J. 1993. Betacellulin: A mitogen from pancreatic beta cell tumors. Science 259:1604-1607.
53. Shoyab M, McDonald VL, Bradley JG, Todaro GJ. 1988. Amphiregulin: A bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7. Proc Natl Acad Sci USA 85:6528-6532.
54. Sigismund S, Woelk T, Puri C, Maspero E, Tacchetti C, Transidico P, Di Fiore PP, Polo S. 2005. Clathrin-independent endocytosis of ubiquitinated cargos. Proc Natl Acad Sci USA 102:2760-2765.
55. Sorkin A, von Zastrow M. 2009. Endocytosis and signalling: Intertwining molecular networks. Nat Rev Mol Cell Biol 10:609-622.
56. Sousa LP, Lax I, Shen H, De Ferguson SM, Camilli P, Schlessinger J. 2012. Suppression of EGFR endocytosis by dynamin depletion reveals that EGFR signaling occurs primarily at the plasma membrane. Proc Natl Acad Sci USA 109:4419-4424.
57. Strachan L, Murison JG, Prestidge RL, Sleeman MA, Watson JD, Kumble KD. 2001. Cloning and biological activity of epigen, a novel member of the epidermal growth factor superfamily. J Biol Chem 276: 18265-18271.
58. Thoresen GH, Guren TK, Sandnes D, Peak M, Agius L, Christoffersen T. 1998. Response to transforming growth factor alpha (TGFalpha) and epidermal growth factor (EGF) in hepatocytes: Lower EGF receptor affinity of TGFalpha is associated with more sustained activation of p42/p44 mitogen-activated protein kinase and greater efficacy in stimulation of DNA synthesis. J Cell Physiol 175:10-18.
59. Toyoda H, Komurasaki T, Uchida D, Takayama Y, Isobe T, Okuyama T, Hanada K. 1995. Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. J Biol Chem 270: 7495-7500.
60. Uberall I, Kolar Z, Trojanec R, Berkovcova J, Hajduch M. 2008. The status and role of ErbB receptors in human cancer. Exp Mol Pathol 84:79-89.
61. Vieira AV, Lamaze C, Schmid SL. 1996. Control of EGF receptor signaling by clathrin-mediated endocytosis. Science 274:2086-2089.
62. Vlacich G, Coffey RJ. 2011. Resistance to EGFR-targeted therapy: A family affair. Cancer Cell 20:423-425.
63. von Zastrow M, Sorkin A. 2007. Signaling on the endocytic pathway. Curr Opin Cell Biol 19:436-445.
64. Watanabe T, Shintani A, Nakata M, Shing Y, Folkman J, Igarashi K, Sasada R. 1994. Recombinant human betacellulin. Molecular structure, biological activities, and receptor interaction. J Biol Chem 269: 9966-9973.
65. Wilson KJ, Mill C, Lambert S, Buchman J, Wilson TR, Hernandez-Gordillo V, Gallo RM, et al. 2012. EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors 30:107-116.
66. Wu P, Wee P, Jiang J, Chen X, Wang Z. 2012. Differential regulation of transcription factors by location-specific EGF receptor signaling via a spatio-temporal interplay of ERK activation. PLoS One 7:e41354.
67. Yagi H, Miyamoto S, Tanaka Y, Sonoda K, Kobayashi H, Kishikawa T, Iwamoto R, et al. 2005. Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer. Br J Cancer 92:1737-1745.
68. Yagi H, Yotsumoto F, Sonoda K, Kuroki M, Mekada E, Miyamoto S. 2009. Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer. Int J Cancer 124:1429-1439.
69. Yotsumoto F, Sanui A, Fukami T, Shirota K, Horiuchi S, Tsujioka H, Yoshizato T, et al. 2009. Efficacy of ligand-based targeting for the EGF system in cancer. Anticancer Res 29:4879-4885.
70. Zhou ZN, Sharma VP, Beaty BT, Roh-Johnson M, Peterson EA, Van Rooijen N, Kenny PA, et al. 2013. Autocrine HBEGF expression promotes breast cancer intravasation, metastasis and macrophage-independent invasion in vivo. Oncogene 33:3784-3793.